A 90-week multi-center randomized double-blind placebo-controlled study in patients with mild Alzheimer
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of the current study is to find out if CAD106 is safe and well tolerated in the presence of an adjuvant.
Description
The purpose of the current study is to find out if CAD106 is safe and well tolerated in the presence of an adjuvant.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's Disease
-
Age: Between 50 Years - 85 Years
-
Gender: All
Updated on
23 Apr 2024.
Study ID: 1010002704 (1003-12)
